We report three new mutations in the gene for aldolase B that are associated with hereditary fructose intolerance (HFI). Two nonsense mutations create opal termination codons: R3op (C-+T, Arg3--ter, exon 2) was found in homozygous form in four affected members of a large consanguineous Turkish pedigree and R59op (C-+T, Arg59-+ter, exon 3) was found on one allele in a woman of Austrian origin known to harbour one copy of the east European mutation, N334K (Asn334-+Lys). The third mutation occurred in a French HFI patient known to be heterozygous for the widespread mutation, A174D (Ala"74-+Asp): a single mutation, G-+A, in the consensus acceptor site 3' of intron 6 was found on the remaining allele. These mutations are predicted to abrogate synthesis of functional protein and thus represent null alleles of aldolase B. The mutant alleles can be readily detected in the amplification refractory mutation system (ARMS) or (for R59op and 3' intron 6) by digestion of amplified genomic fragments with DdeI or AlwNI, respectively, to facilitate direct diagnosis of HFI by molecular analysis of aldolase B genes.
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Figure I Pedigree of a Turkish family affected by hereditary fructose intolerance showing symptomatic and asymptomatic sibs of the proband marked by an arrow. The proband's mother had suffered one stillbirth and several spontaneous abortions, as depicted. In addition, severe intolerance offructose containing foods had been reported by two forebears, who had died in adult life, and affected several living collateral relatives. Small Hereditary fructose intolerance (HFI) results from a deficiency of aldolase B (fructose-bisphosphate aldolase, EC 4.1.2.13) in the liver, intestine, and kidney.' The disorder is inherited as an autosomal recessive trait and studies from Switzerland estimate a frequency of 1 in 20 000 live births.2 HFI is characterised by abdominal symptoms, especially vomiting, that follow ingestion of fructose and related sugars. The symptoms are accompanied by hypoglycaemia, hypophosphataemia, and acidosis.3 Affected infants usually develop a protective aversion to sweet tasting foods and drinks but persistent exposure to harmful sugars leads to growth retardation, hepatic injury, and eventually death.4 However, the condition responds dramatically to a sugar exclusion diet and, once recognised, is compatible with a normal life expectancy. The mainstay of diagnosis is the intravenous fructose tolerance test but this procedure, and others based on enzymatic assay of tissue biopsy samples or 31P magnetic resonance spectroscopy,5 are too cumbersome or invasive for general use in the population.
The human gene encoding aldolase B has been fully characterised: it maps to chromosome 9q21.3--q22.2 and contains nine exons, the first of which is untranslated.67 Lately, we have identified mutations in this gene that are associated with HFI and have applied these findings to the diagnosis of the condition by direct analysis of genomic DNA."' Hitherto, three missense mutations in the human aldolase B gene have been found to be widely distributed: the mutations A149P, (Ala149-) Pro, G-+C exon 58-1'), A174D, (Ala'74--Asp, C--+A exon 51'), and N334K, (Asn334-÷Lys, C--*G exon 9") are prevalent in European patients with HFI and are thus of diagnostic significance. However, until a more complete picture of the distribution of aldolase B mutations emerges, genetic diagnosis and screening for HFI will be limited to specific populations in which the allele frequencies can be predicted.9 Rare mutant alleles of aldolase B can be overlooked and result in failure to diagnose the condition by this means.
We report here three previously unknown mutations that inactivate aldolase B and have been identified in patients with HFI originating respectively from eastern Turkey, Austria, and France. We also describe simple methods for mutation analysis using the polymerase chain reaction (PCR). The procedures require only minute quantities of genomic DNA to establish the presence of these disease alleles in patients in whom HFI is suspected. (fig 3A) . However, for the proband, only infant from France carried one copy of the the R3op or mutant primer gave rise to the N334K and A174D alleles, respectively.
amplified product, confirming that this patient To identify aldolase B mutations in the was homozygous for R3op. This genotype was uncharacterised alleles, individual exons and assigned to the patient's three symptomatic splice junction sites were amplified in the PCR sibs ( fig 3A, lanes 3, 7, and 8 ) who gave rise to and sequenced. In the proband of the Turkish the same 156 base pair product only when the family, a C-+T transition in the first base R3op primer was used in the PCR. Similar of the arginine codon at position 3 in exon analysis of DNA from both parents and two 2 generated the opal termination codon remaining asymptomatic sibs ( fig 3A, lanes 1,  T(U) GA, designated R3op. Inspection of the 2, 5, and 6) where products were obtained in double stranded sequencing ladder indicated the ARMS using wild type and mutant that the patient was homozygous for this non-primers, indicated heterozygosity for R3op. sense mutation (fig 2A) .
The results showed that symptomatic disease Since the mutation neither creates nor des-was only associated with homozygosity for the troys a restriction enzyme recognition site, the R3op mutation and that consanguinity had led amplification refractory mutation system to transmission of two copies of a mutant allele (ARMS)'3 was used to confirm the segregation of aldolase B that were identical by descent of R3op. The ARMS, which is a modification from a common ancestor. of the PCR, was carried out in the presence of Direct sequencing of exon 3 of aldolase B an exon 2 antisense oligonucleotide primer after amplification of DNA obtained from the (E2 +) and sense primers for the wild type proband of the Austrian family with HFI (R3+) or mutant alleles (R3op), respectively. showed a C-÷T transition of the first base of The sense primers differ only at their 3' end by arginine codon at position 59, also generating a single base, so that discriminatory amplifica-an opal termination signal, R59op ( fig 2B) . tion will occur according to the presence of the This nonsense mutation creates a new recogniwild type or mutant sequences in the template tion site for the restriction endonuclease DdeI, DNA. We observed that DNA obtained from a thus allowing ready confirmation of its preshealthy subject gave the predicted 156 base ence in genomic DNA ( fig 3B) A174D/3' intron 6, G-+A. 
